The STRIVE trial is designed to evaluate the safety and efficacy of the vaccine to determine if it prevents postoperative invasive S. aureus infections in patients undergoing elective
The company’s therapy, called 514G3, was developed from a human donor with natural antibodies effective at neutralizing MRSA and non-MRSA forms of S. aureus. According to the company,
CAT-1004 inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays a major role in muscle health. DMD involves progressive muscle
Acebilustat, a once-daily oral drug candidate, is currently being evaluated for the treatment of inflammatory diseases. The drug is a new small molecule inhibitor of Leukotriene A4 Hydrolase
The NDA is based on the results of a large, multicenter, open-label, randomized, Phase III trial that examined the repeated use of Amphora gel compared to a vaginal
Novella provides clinical trial services for small to mid-sized oncology companies. ImmunoCellular chief executive officer Andrew Gengos said: "Establishing this agreement with Novella Clinical moves us one more
Strensiq (asfotase alfa), a bone-targeted enzyme replacement therapy, is the first such treatment to be approved in Japan for HPP patients. The company intends to start commercial treatment
The deal amount was paid by Cardinal to Court Square Capital Partners using existing cash and new debt following the receipt of regulatory approvals and satisfying other customary
As part of the deal, Glycotope will be Cantargia’s production partner to obtain material for the clinical studies of CAN04 in cancer patients. The deal will also see
The trial is being carried out by clinicians at Cedars-Sinai, Los Angeles, who were awarded a grant from The National Institute of Diabetes and Digestive and Kidney Diseases
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.